Veeva Systems (VEEV) Unveils Falcon, An Agentic Platform Built For Life Sciences Drug Development Processes

Veeva Systems Inc. (NYSE: VEEV ), with significant hedge fund interest, ranks among the 10 best SaaS stocks to buy according to hedge funds . As of Q1 2026, 62 hedge funds held bullish positions in the stock, representing $2.95 billion in aggregate value, as per Insider Monkey data.

This week, Veeva Systems Inc. (NYSE:VEEV) is accelerating its efforts to deepen its footprint across the life sciences industry, securing major global CRM commitments while rolling out new AI-driven automation tools for drug development. On May 28, 2026, Veeva Systems Inc. (NYSE:VEEV) announced that Kindeva, a contract development and manufacturing organization, is adopting Veeva Quality Cloud to unify its global network of sites onto a single platform. The deployment includes Veeva QualityDocs, Veeva QMS, Veeva Training, and Veeva LearnGxP. Kindeva said the platform will standardize quality assurance and training processes, eliminate data silos, and support growth across regions and therapeutic areas. That announcement followed a pair of CRM commitments disclosed on May 27, 2026. Merck KGaA (Darmstadt, Germany) committed globally to Veeva Vault CRM, with the company’s CIO citing consistent processes and data connectivity as priorities. On the same day, Teva Pharmaceuticals also committed to Vault CRM globally, with Teva saying the platform will provide a technical foundation for commercial execution. Vault CRM is part of Veeva Systems Inc. (NYSE:VEEV)’s broader Vault CRM Suite and includes AI agents designed to drive commercial efficiency. Also on May 27, 2026, Veeva Systems Inc. (NYSE:VEEV) unveiled Falcon, an agentic platform built for life sciences drug development processes. Falcon works with Veeva Development Cloud applications across clinical, regulatory, and safety functions. Initial focus areas include trial master file document intake, health authority correspondence, and safety case triage. CEO Peter Gassner called it Veeva’s first offering in agentic labor, with early adopter availability planned for November 2026. Veeva Systems Inc. (NYSE:VEEV) is a provider of cloud-based solutions for the global life sciences industry. Its offerings include cloud software, artificial intelligence, data, and business consulting. While we acknowledge the potential of VEEV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock . READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years . Disclosure: None. Follow Insider Monkey on Google News .

This report comes from Yahoo Finance. The story centres on Veeva Systems (VEEV) Unveils Falcon, An Agentic Platform Built For Life Sciences Drug Development Processes. Full coverage and background context is available at the original source. Readers seeking more detail on this developing topic are encouraged to follow updates from Yahoo Finance and related outlets covering this beat.